NMS-03592088 (novel investigational agent for AML/CMML)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-18 — Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML: Phase I first-in-human trial registered evaluating safety, tolerability, MTD/RP2D, and preliminary antitumor activity of NMS-03592088 in adults with relapsed/refractory AML or CMML (mechanism not described in abstract). (novelty: 3)
Open questions
Related
Contributing findings
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
18-mar-2026
novelty 3
per-area 3
introduces